Partial Cellular Reprogramming, In Vivo

Partial cellular reprogramming has been demonstrated in laboratory models to reverse cellular aging without inducing tumors. The CureForge In-Vivo Reprogramming Institute is the federation’s research engine for translating that capability to humans. Eleven specialized AI systems collaborate across reprogrammingfactor pharmacodynamic modulator design, adeno-associated-virus delivery optimization coordinated with the gene-editing and physical-world institutes, reprogramming dose-response modeling, teratoma-risk prediction through cell-fate trajectory simulation, organ-by-organ rejuvenation timing coordinated with the seventyeight-organ institute, partial-reprogramming protocol optimization, plasma fractions therapeutic design, Yamanaka-factor cycling coordination, reprogramming-andsenolytic combination protocols coordinated with the programmed-death institute, induced-pluripotent stem-cell derivation cross-talk with the stem-cell institute, and adversarial review of every reprogramming claim before publication.

Value proposition:

• Partial cellular reprogramming as a tractable engineering target
• Teratoma-risk prediction through cell-fate trajectory simulation
• Organ-by-organ rejuvenation timing coordinated across the federation